The Belfast-based health technology firm secured Series A backing from investors including Wharton Asset Management and IQ Capital to advance its neurological research and medical trials.
"We are delighted to receive this latest wave of funding, it will enable us to continue to lead the way in developing non-invasive neuro-stimulation technology and will propel our work to a whole new level,"
The investment was led by Alex Snodgrass, Jack Teasdale, and Tim Rea from BGF.
"Invenio was set up on the core values of exceptional customer focus, deep industry and technology expertise, transparency and employee care. Our core values, a unique culture and a highly valued customer engagement model have helped us grow over the last thirteen years and maintain deep relationships with our clients. We are delighted to have BGF on board for the next stage of our journey and are looking forward to making the most of the team’s expertise in this space. BGF’s investment will help us continue to invest and grow to meet demand, whilst keeping control of our business and staying true to our values."
The Series A round was led by Point72 Ventures to support conversational AI deployment in contact centres.
"Developing sophisticated AI technology while formulating a compelling SaaS proposition is a significant challenge, and it has delayed the real-world deployment of conversational AI for far too long,"